A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke
NEJM 382:9-19,81, Amarenco, P.,et al, 2020
Clinicopathologic Conference, Statin-Associated Autoimmune Myopathy
NEJM 381:275-283, Case 22-2019, 2019
Primary Prevention of Stroke
JAMA 316:658-659, Steiger, N. & Cifu, A.S., 2016
Sporadic Cerebral Amyloid Angiopathy Revisited: Recent Insights Into Pathophysiology and Clinical Spectrum
JNNP 83:124-137, Charidimou,A.,et al, 2012
Clinicopathologic Conference,Necrotizing Noninflammatory Myopathy Consistent with Exposure to Statins
NEJM 36:944-954, Case 7-2012, 2012
Secondary Prevention after Ischemic Stroke or Transient Ischemic Attack
NEJM 366:1914-1922;, Davis, S.M. & Donnan, G.A., 2012
The "Million Hearts" Initiative - Preventing Heart Attacks and Strokes
NEJM 365:e27, Frieden, T.R.,et al, 2011
Relative Effects of Statin Therapy on Stroke and Cardiovascular Events in Men and Women: Secondary Analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study
Stroke 39:2444-2448, Goldstein,L.B.,et al., 2008
Antiplatelets, ACE Inhibitors, and Statins Combination Reduces Stroke Severity and Tissue At Risk
Neurol 66:1153-1158, Kumar,S.,et al, 2006
Expanding Indications for Statins in Cerebral Ischemia
Arch Neurol 62:67-72,23, Ovbiagele,B.,et al, 2005
Effect of Pravastatin on Cerebral Infarcts and White Matter Lesions
Neurol 64:1807-1809, ten Dam,V.H.,et al, 2005
Underappreciated Statin-Induced Myopathic Weakness Causes Disability
Neurorehabil Neural Repair 19:259-263, Dobkin,B.H., 2005
Oral Simvastin Treatment in Relapsing-Remitting Multiple Sclerosis
Lancet 363:1607-1608,1570, Vollmer,T.,et al, 2004
HMG-CoA Reductase Inhibitors (Statins)
Neurol 54:790-795, Hess,D.C.,et al, 2000
Pravastatin Therapy and The Risk of Stroke
NEJM 343:317-326, White,H.D. et al, 2000